Indication |
For the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity. |
Pharmacodynamics |
Medrysone is a topical anti-inflammatory corticoidsteroids for
ophthalmic use. In patients with increased intraocular pressure and in
those susceptible to a rise in intraocular pressure, there is less
effect on pressure with medrysone than with dexamethasone or
betamethasone. Corticoidsteroids inhibit the edema, fibrin deposition,
capillary dilation, and phagocytic migration of the acute inflammatory
response, as well as capillary proliferation, deposition of collagen,
and scar formation. |
Mechanism of action |
There is no generally accepted explanation for the mechanism of
action of ocular corticosteroids. However, corticosteroids are thought
to act by the induction of phospholipase A2 inhibitory proteins,
collectively called lipocortins. It is postulated that these proteins
control the biosynthesis of potent mediators of inflammation such as
prostaglandins and leukotrienes by inhibiting the release of their
common precursor, arachidonic acid. Arachidonic acid is released from
membrane phospholipids by phospholipase A2. Initially, the drug binds to
the glucocorticoid receptor in the cytosol. This migrates to the
nucleus and binds to genetic elements which cause activation and
repression of the involved genes in the inflammatory pathway. |
Absorption |
Rapidly absorbed following oral administration. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Not Available |
Route of elimination |
Not Available |
Half life |
Not Available |
Clearance |
Not Available |
Toxicity |
Not Available |
Comments
Post a Comment